The fibroblast growth factor receptor 4 (FGFR4) alterations play an essential role in developing cancer in the breast, ovarian, prostate, colon, rhabdomyosarcoma, pancreatic, and gastric, hepatocellular, and pituitary adenocarcinomas. This evidence concerns the gene FGFR4 and rhabdomyosarcoma.